Moore GW - Search Results

1

Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors.

Kumano O, Amiral J, Dunois C, Peyrafitte M, Moore GW. Kumano O, et al. Among authors: moore gw. Int J Lab Hematol. 2021 Aug;43(4):771-778. doi: 10.1111/ijlh.13571. Epub 2021 May 11. Int J Lab Hematol. 2021. PMID: 33974363

2

The Activated Seven Lupus Anticoagulant (ASLA) assay: a new test for lupus anticoagulants (LAs). Evidence that some LAs are detectable only in extrinsic pathway-based assays.

Moore GW, Smith MP, Patel Y, Savidge GF. Moore GW, et al. Blood Coagul Fibrinolysis. 2002 Apr;13(3):261-9. doi: 10.1097/00001721-200204000-00013. Blood Coagul Fibrinolysis. 2002. PMID: 11943941

3

Heterogeneity of Russell's viper venom affects the sensitivity of the dilute Russell's viper venom time to lupus anticoagulants.

Moore GW, Savidge GF. Moore GW, et al. Blood Coagul Fibrinolysis. 2004 Apr;15(3):279-82. doi: 10.1097/00001721-200404000-00015. Blood Coagul Fibrinolysis. 2004. PMID: 15060428

4

Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin's lymphoma.

Moore GW, Kamat AV, Gurney DA, O'Connor O, Rangarajan S, Carr R, Savidge GF. Moore GW, et al. Clin Lab Haematol. 2004 Dec;26(6):429-34. doi: 10.1111/j.1365-2257.2004.00644.x. Clin Lab Haematol. 2004. PMID: 15596003

5

Low frequency of elevated prothrombin times in patients with lupus anticoagulants when using a recombinant thromboplastin reagent: implications for dosing and monitoring of oral anticoagulant therapy.

Moore GW, Rangarajan S, Holland LJ, Henley A, Savidge GF. Moore GW, et al. Br J Biomed Sci. 2005;62(1):15-8; quiz 47. doi: 10.1080/09674845.2005.11732681. Br J Biomed Sci. 2005. PMID: 15816206

6

A new-generation dilute Russell's viper venom time assay system for lupus anticoagulants: evaluation of detection utilising frozen reagents and controls.

Moore GW, Tugnait S, Savidge GF. Moore GW, et al. Br J Biomed Sci. 2005;62(3):127-32. doi: 10.1080/09674845.2005.11732699. Br J Biomed Sci. 2005. PMID: 16196459

7

The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied.

Moore GW, Savidge GF. Moore GW, et al. Thromb Res. 2006;118(4):523-8. doi: 10.1016/j.thromres.2005.09.010. Epub 2005 Nov 2. Thromb Res. 2006. PMID: 16263154

8

Further evidence of false negative screening for lupus anticoagulants.

Moore GW, Henley A, Greenwood CK, Rangarajan S. Moore GW, et al. Thromb Res. 2008;121(4):477-84. doi: 10.1016/j.thromres.2007.05.018. Epub 2007 Jun 28. Thromb Res. 2008. PMID: 17602725

9

The activated seven lupus anticoagulant assay detects clinically significant antibodies.

Moore GW, Rangarajan S, Savidge GF. Moore GW, et al. Clin Appl Thromb Hemost. 2008 Jul;14(3):332-7. doi: 10.1177/1076029607305099. Epub 2007 Sep 25. Clin Appl Thromb Hemost. 2008. PMID: 17895508 Free article.

10

Lupus anticoagulant detection: out of control?

Moore GW, Brown KL, Bromidge ES, Drew AJ, Ledford-Kraemer MR. Moore GW, et al. Int J Lab Hematol. 2013 Apr;35(2):128-36. doi: 10.1111/ijlh.12006. Epub 2012 Sep 17. Int J Lab Hematol. 2013. PMID: 22978522

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

319 results

Search Page